The updated AIFA rules for PCSK9 inhibitors reimbursement increase the number of patients who could benefit from this treatment by 14.4%, including more patients in secondary prevention for cardiovascular diseases. This evidence concerns the gene PCSK9 and cardiovascular disorder.